Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions:…
An institutional-grade, numbers-driven thesis on BIO — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of August 16, 2026, TradersQuant's model rates Bio-Rad Laboratories, Inc. (BIO) 67/100 with a 12-month base-case forecast of $350.00 — -1.8% versus the current price of $356.26. Bio-Rad Laboratories, Inc. trades at $356.26 in the Healthcare sector, with a market capitalisation of $9.59B. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month analyst consensus price target for BIO is $350.00, implying -1.8% versus the current price. The model's 12-month scenario range runs from $400.43 (bear) to $537.11 (bull), with a base case of $447.19.
On the fundamentals, Bio-Rad Laboratories shows a P/E of 42.8, trailing revenue of $2.58B, revenue growth of +0.7% YoY. This page also tracks BIO's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
BIO currently carries a TradersQuant composite score of 67/100, which we read as a neutral-to-watch signal. The Wall-Street analyst consensus is "Buy". Our 12-month price target of $350.00 implies -1.8% from $356.26. This is research, not financial advice — always combine it with your own judgement.
The analyst consensus price target for BIO is $350.00, about -1.8% versus the latest price of $356.26. Consensus is based on 14 analysts.
TradersQuant's 12-month model forecast for BIO is a base case of $447.19, ranging from $400.43 (bear) to $537.11 (bull), an expected return of +25.5%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for BIO over the next 12 months is $447.19 in the base case (bear $400.43, bull $537.11), versus today's price of $356.26. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for BIO — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates BIO's fair value at $350.00, implying -1.8% of expected upside versus the current price.
Bio-Rad Laboratories does not currently pay a dividend.
Data and model outputs are for research only and are not financial advice. Figures update continuously.
